Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02489500 · ClinicalTrials.gov registry record · Phase 3
Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
A Phase 3 study, sponsored by Boston Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT02489500: Clinical Trial Phase 3 study, sponsored by Boston Medical Center.
NCT02489500 is a Phase 3 study that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 3 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02489500, a Phase 3 study, was terminated before completion, sponsored by Boston Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
Standard treatment for AL Amyloidosis is high-dose melphalan and stem cell transplant. This study will compare the safety and effectiveness of standard treatment with high-dose melphalan and stem cell transplant, compared with investigational bortezomib when used in combination with standard treatment with high-dose melphalan and stem cell transplant for AL amyloidosis.
Primary Outcome
Hematologic response defined as: at least 50% improvement in the difference between involved and uninvolved free light chains
Interventions
- DRUG Melphalan
- DRUG Bortezomib
- PROCEDURE Stem cell infusion
- DRUG Neupogen
- PROCEDURE Stem Cell Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-04-28 |
| Phase | Phase 3 |
Why NCT02489500 stopped before completion
NCT02489500 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT02489500 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02489500 about?
NCT02489500 is a clinical study titled "Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib". Standard treatment for AL Amyloidosis is high-dose melphalan and stem cell transplant. This study will compare the safety and effectiveness of standard treatment with high-dose melphalan and stem cell transplant, compared with investigational bortezomib when used in combination with standard treatm...
What is the current status of trial NCT02489500?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2015-06. Estimated completion is 2017-04-28.
What interventions are being tested in trial NCT02489500?
The interventions under investigation include: Melphalan (DRUG), Bortezomib (DRUG), Stem cell infusion (PROCEDURE), Neupogen (DRUG), Stem Cell Collection (PROCEDURE).
Who is sponsoring clinical trial NCT02489500?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02489500's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia